Studying Treatments in patients receiving androgen deprivation therapy (ADT) for Metastatic Prostate Cancer: Evaluation of Drug and radiation Efficacy: A 2nd multi-arm multi-stage randomised controlled trial (STAMPEDE2)

Status

Not yet recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-522145-21-00

Enrollment

Registered

2026-02-25

Start date

Unknown

Completion date

Unknown

Last updated

2026-02-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metastatic hormone sensitive prostate cancer

Brief summary

For both Comparisons S and P, the primary outcome is Overall Survival (OS) defined as time from randomisation to death from any cause.

Detailed description

Failure-Free Survival (FFS), Radiographic Progression-Free-Survival (rPFS), Prostate cancer specific survival (PCSS), Safety, toxicity and compliance, Quality of life, Cost and resources.

Interventions

DRUGPluvicto 1 000 MBq/mL solution for injection/infusion

Eligibility

Sex/Gender

Male

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
For both Comparisons S and P, the primary outcome is Overall Survival (OS) defined as time from randomisation to death from any cause.	—

Secondary

Measure	Time frame
Failure-Free Survival (FFS), Radiographic Progression-Free-Survival (rPFS), Prostate cancer specific survival (PCSS), Safety, toxicity and compliance, Quality of life, Cost and resources.	—

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 26, 2026